Epigenetic inactivation of BCL6B, a novel functional tumour suppressor for gastric cancer, is associated with poor survival

Gut

Volumn 61, Issue 7, 2012, Pages 977-985

  Xu, Lixia ^a,b   Li, Xiaoxing ^a   Chu, Eagle S H ^a   Zhao, Guijun ^a   Go, Minnie Y Y ^a   Tao, Qian ^a   Jin, Hongchuan ^a   Zeng, Zhirong ^b   Sung, Joseph J Y ^a   Yu, Jun ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSE; ATM PROTEIN; CALVASCULIN; CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; PROTEIN BCL 6; PROTEIN P53; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 1A; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ADULT; APOPTOSIS; ARTICLE; BCL6B GENE; CANCER SURVIVAL; CELL GROWTH; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE SILENCING; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METHYLATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STOMACH CANCER; SURVIVAL RATE; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; DNA METHYLATION; EPIGENOMICS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MICE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; REPRESSOR PROTEINS; SEQUENCE ANALYSIS, DNA; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84861574581     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2011-300411     Document Type: Article

References (36)

1. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006;12:354-62.
2. Choi IS, Wu TT. Epigenetic alterations in gastric carcinogenesis. Cell Res 2005;15:247-54.
3. Yu J, Leung WK, Lee TL, et al. Promoter hypermethylation of cyclooxygenase-2 in gastric carcinoma. Int J Oncol 2003;22:1025-31.
4. Cheng YY, Yu J, Wong YP, et al. Frequent epigenetic inactivation of secreted frizzled-related protein 2 (SFRP2) by promoter methylation in human gastric cancer. Br J Cancer 2007;97:895-901.
5. Cheng YY, Jin H, Liu X, et al. Fibulin 1 is downregulated through promoter hypermethylation in gastric cancer. Br J Cancer 2008;99:2083-7.
6. Ying J, Poon FF, Yu J, et al. DLEC1 is a functional 3p22.3 tumour suppressor silenced by promoter CpG methylation in colon and gastric cancers. Br J Cancer 2009;100:663-9.
7. Yu J, Cheng YY, Tao Q, et al. Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology 2009;136:640-51.e1.
8. Yu J, Tao Q, Cheng YY, et al. Promoter methylation of the Wnt/beta-catenin signaling antagonist Dkk-3 is associated with poor survival in gastric cancer. Cancer 2009;115:49-60.
9. Ying J, Srivastava G, Hsieh WS, et al. The stress-responsive gene GADD45G is a functional tumor suppressor, with its response to environmental stresses frequently disrupted epigenetically in multiple tumors. Clin Cancer Res 2005;11:6442-9.
10. Okabe S, Fukuda T, Ishibashi K, et al. BAZF, a novel Bcl6 homolog, functions as a transcriptional repressor. Mol Cell Biol 1998;18:4235-44.
11. Sakashita C, Fukuda T, Okabe S, et al. Cloning and characterization of the human BAZF gene, a homologue of the BCL6 oncogene. Biochem Biophys Res Commun 2002;291:567-73.
12. Manders PM, Hunter PJ, Telaranta AI, et al. BCL6b mediates the enhanced magnitude of the secondary response of memory CD8+ T lymphocytes. Proc Natl Acad Sci U S A 2005;102:7418-25.
13. Zhang H, Okada S, Hatano M, et al. A new functional domain of Bcl6 family that recruits histone deacetylases. Biochim Biophys Acta 2001;1540:188-200.
14. Ushijima T, Morimura K, Hosoya Y, et al. Establishment of methylation-sensitiverepresentational difference analysis and isolation of hypo- and hypermethylated genomic fragments in mouse liver tumors. Proc Natl Acad Sci U S A 1997;94:2284-9.
15. Tao Q, Huang H, Geiman TM, et al. Defective de novo methylation of viral and cellular DNA sequences in ICF syndrome cells. Hum Mol Genet 2002;11:2091-102.
16. Razin A. CpG methylation, chromatin structure and gene silencing-a three-way connection. EMBO J 1998;17:4905-8.
17. Oatley JM, Avarbock MR, Telaranta AI, et al. Identifying genes important for spermatogonial stem cell self-renewal and survival. Proc Natl Acad Sci U S A 2006;103:9524-9.
18. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002;2:277-88.
19. Hsu H, Shu HB, Pan MG, et al. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 1996;84:299-308.
20. Muzio M, Chinnaiyan AM, Kischkel FC, et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996;85:817-27.
21. Chopra DP, Menard RE, Januszewski J, et al. TNF-alpha-mediated apoptosis in normal human prostate epithelial cells and tumor cell lines. Cancer Lett 2004;203:145-54.
22. Rathmell JC, Thompson CB. The central effectors of cell death in the immune system. Annu Rev Immunol 1999;17:781-828.
23. Mahon PC, Baril P, Bhakta V, et al. S100A4 contributes to the suppression of BNIP3 expression, chemoresistance, and inhibition of apoptosis in pancreatic cancer. Cancer Res 2007;67:6786-95.
24. Abramovich D, Parborell F, Tesone M. Effect of a vascular endothelial growth factor (VEGF) inhibitory treatment on the folliculogenesis and ovarian apoptosis in gonadotropin-treated prepubertal rats. Biol Reprod 2006;75:434-41.
25. Xia L, Fu GS, Yang JX, et al. Endothelial progenitor cells may inhibit apoptosis of pulmonary microvascular endothelial cells: new insights into cell therapy for pulmonary arterial hypertension. Cytotherapy 2009;11:492-502.
26. Musgrove EA, Lee CS, Buckley MF, et al. Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc Natl Acad Sci U S A 1994;91:8022-6.
27. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
28. Paternot S, Bockstaele L, Bisteau X, et al. Rb inactivation in cell cycle and cancer: the puzzle of highly regulated activating phosphorylation of CDK4 versus constitutively active CDK-activating kinase. Cell Cycle 2010;9:689-99.
29. Chang HY, Sneddon JB, Alizadeh AA, et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004;2:E7.
30. Stephens RW, Nielsen HJ, Christensen IJ, et al. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 1999;91:869-74.
31. Pusapati RV, Rounbehler RJ, Hong S, et al. ATM promotes apoptosis and suppresses tumorigenesis in response to Myc. Proc Natl Acad Sci U S A 2006;103:1446-51.
32. Banin S, Moyal L, Shieh S, et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 1998;281:1674-7.
33. Canman CE, Lim DS, Cimprich KA, et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 1998;281:1677-9.
34. Appella E, Anderson CW. Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 2001;268:2764-72.
35. Deng X, Ljunggren-Rose A, Maas K, et al. Defective ATM-p53-mediated apoptotic pathway in multiple sclerosis. Ann Neurol 2005;58:577-84.
36. Park YJ, Claus R, Weichenhan D, et al. Genome-wide epigenetic modifications in cancer. Prog Drug Res 2011;67:25-49.